Design and evaluation of selective butyrylcholinesterase inhibitors based on Cinchona alkaloid scaffold.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 30289893.
- Also identified by DOI 10.1371/journal.pone.0205193 and PMC identifier 6173406.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
This paper describes the synthesis and anticholinesterase potency of Cinchona-based alkaloids; ten quaternary derivatives of cinchonines and their corresponding pseudo-enantiomeric cinchonidines. The quaternization of quinuclidine moiety of each compound was carried out with groups diverse in their size: methyl, benzyl and differently meta- and para-substituted benzyl groups. All of the prepared compounds reversibly inhibited human butyrylcholinesterase and acetylcholinesterase with Ki constants within nanomolar to micromolar range. Five cinchonidine derivatives displayed 95-510 times higher inhibition selectivity to butyrylcholinesterase over acetylcholinesterase and four were potent butyrylcholinesterase inhibitors with Ki constants up to 100 nM, of which N-para-bromobenzyl cinchonidinium bromide can be considered a lead for further modifications and optimizations for possible use in the treatment of neurodegenerative diseases.
Medical subject headings
- Butyrylcholinesterase
- Cholinesterase Inhibitors
- Cinchona Alkaloids
- Drug Design
- Neurodegenerative Diseases